Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 15/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.57 |
| ▸ | CDK7 | P50613 | 2/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | CDK4 | P11802 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CCND1 | P24385 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | CCND3 | P30281 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4120947 | 0.87 | ITK (0.81) | ITKCHEK1CDK7 | |
| SCHEMBL145864 | 0.82 | ITK (1.00) | ITKCHEK1FGFR1CDK4CCNA2 | |
| SCHEMBL29470244 | 0.81 | ITK (1.00) | ITKCHEK1 | |
| SCHEMBL145584 | 0.81 | ITK (1.00) | ITKCHEK1 | |
| SCHEMBL5321885 | 0.81 | ITK (0.66) | ITKCHEK1CDK7FGFR1CDK4 | |
| SCHEMBL5061389 | 0.81 | ITK (0.67) | ITKCHEK1CDK7 | |
| SCHEMBL5061452 | 0.80 | ITK (0.66) | ITKCHEK1CDK7 | |
| SCHEMBL142590 | 0.80 | ITK (0.73) | ITKCHEK1FGFR1CDK4CCNA2 | |
| SCHEMBL141689 | 0.80 | ITK (0.73) | ITKCHEK1FGFR1CDK4CCNA2 | |
| SCHEMBL5637262 | 0.80 | ITK (0.73) | ITKCHEK1FGFR1CDK4CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101884-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-09-05 | — | — | US | claimed |
| US-20050070546-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | claimed |
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-7101884-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| WO-2005065686-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) | 2005-07-21 | — | — | WO | disclosed |
| US-20050070546-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| WO-2003024969-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | ITK 2496/4885CHEK1 3154/4885CDK7 2224/4885 |
| US-20050070546-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | ITK 377/4885CHEK1 499/4885CDK7 282/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | ITK 2496/4885CHEK1 3154/4885CDK7 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.